April 19, 2018 / 5:54 AM / 8 months ago

BRIEF-Mithra Pharmaceuticals Announces Positive Donesta Phase IIb Study

April 19 (Reuters) - MITHRA PHARMACEUTICALS SA:

* ANNOUNCES POSITIVE DONESTA PHASE IIB STUDY ACHIEVING PRIMARY OBJECTIVE AND CONFIRMING PROMISING SAFETY PROFILE

* STUDY CONCLUDED THAT 15 MG OF E4 WAS OPTIMAL ORAL MINIMUM DOSE FOR EFFECTIVE TREATMENT OF VMS.

* THIS DOSE COHORT DEMONSTRATES REDUCTION OF OVER 80% IN FREQUENCY OF MODERATE TO SEVERE VMS WHEN COMPARED TO BASELINE. Source text : bit.ly/2qKQ8h7 Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below